You read this week’s publication New Cannabis Ventures Weekly Newsletter we publish from October 2015. We no longer send them. By mail as before but we post this and all newsletters On our website hereA number
Friends,
The Cannabis Global stock index had a rough beginning until September. After 45.5% growth in August and increased by 54.2% after the end of the month, the figure decreased from 7.74 to 6.99 in just two days. The result is now only 1.6% per annum. The Great Cannabis Etf MSOS, which is 21.0%, decreased by 17.2% in late August.
Currently there are 23 shares in the Global Cannabis stock index, and they are now 39.2% now. The return frame is from -19.6% to + 186.0%.
There are more than doubled three shares in late June and 13 are two-digit winners. In the last 2nds of June, two shares that have been added to the index are double digit dismantling.
Leading three shares are Canadian LPs, and this newsletter has called the best two coats this year this year. Of course, I alerted here TILRAY is a dangerous stock On August 20, and while he fell a lot from his last peak, it is still higher than at that time (and it is dangerous to stay.)
Today I want to give some caution on some of these names and explain why I’m worried. I have written articles about some, looking for alpha, which are carbon (Tilre and farms), and I continue to be very negative on MSOS ETF (bad diversification). I will celebrate the shares that are in the Global Cannabis stock index, which depict me in alphabetical order.
Aurora Cannabis (ACB)I was closely following this one but it’s no longer on my focus list to 420 investors. The company exploded it in Canada’s adult market, but it has expanded internationally medical hemp. I don’t think the General Director has done a good job, and the shares that make up 15.4% a year as if they are not attractive.
Canopy growth (CGC): I’m closely following CGC and I have been very negative on it for a while. It has become exclusively cannabis, but it continues to harm its actions and fight with many debts. The share decreased by 49.1% to time, and I design it will post a new time low.
Glass Home Brands (Glasf)I don’t contain this one in my focus list, but I pay attention to it, because it is only three MSOS index. I like the CEO, but I think the stock is overestimated. Two investors have been supported who support the Fund very loudly. Glasf is 21.7% per annum.
Rhythm (force): This one, who was known as Agri, was difficult to start in September, but it is 23.0% per annum. I wrote about it before here and I’ve watched it even though it’s not in my focus list. I am interested, because the green thumb industry has such a large share. While I love the idea of haunting beverage-based drinks, the company has a lot of work to do to justify its mass assessment.
SNDL (SNDL): I don’t contain this one in my focus list, but I said to the CEO I like me. The company has what I consider bad MSOS, and it now trades on the value of a tangible book. It makes 40.5% a year.
TILRAY brands (TLRY): I started providing Tlry for a long time since I was not satisfied. I appreciate the better balance and likes what the company does with the drinks in the United States, but the fund, which now goes down by 10.9%, seems very expensive. Share-Count has exploded. One year from now on my target is essentially below if the shares trade and the company does not benefit from transformation.
Trulieve (TCNNF)To date, 44.7%, shares are cheaply designed with adjusted EBITDA. I think that the margins expected by analysts are too high, and I am very careful for Florida, where it is quite large. I also don’t like the balance sheet that has many tax liabilities. If 280E tax is clinging around, this one will fall sharply.
Village farms (VFF)Although it has fallen from the last peak, it still ends 234.6% a year. I think it’s a good company and looks like a transformation, but the fund looks ahead of her. The company could receive a medical cannabis license in Texas, but it may not be. I loved it under $ 1. While I don’t expect it to be a lot I think it could fall a lot.
I covered here just stocks that are in Cannabis Global Stock Index, although there are shares that are not in the indumin. I wrote about some of them while looking for Alpha and I recently parted the post in my blog some cannabis shares that refer to meA number
If I didn’t mention a share with me I don’t want readers to believe the name I like at the current price. My model portfolio has 19.3% cash in the 420 investors, which is about 20%, and positions in two Canadian LPS, two MSOS and three auxiliary names. I try to create a portfolio that has less flaws than Cannabis Global Stock Index.
Any trader or investor that counts 280e taxes can see this to happen. I don’t suppose that it will be, but luck for all those who bet it will be.
Frankly,
Alan
This week’s newsletter is sponsored by Paul. Sapperstein Co.
On September 16, community growth partners are auction in North Massachusetts, etc. All applications must be delivered online. Learn more About 219 points about the auction auction.
Interested parties can contact Michael Saperstein 617-227-6553 or email msaperstein@pesco.comA number
New hemp enterprises publish medicine articles, as well as exclusive news. Here is what we published this last week.
To get real-time updates as our Facebook page or follow Alan RationSharing a number and discover industry news along with supporters, the largest hemp group and entrepreneurs group ConnectionA number
Stay on top of some important communications of public companies by watching upcoming Cannabis Investor Calendar:A number
Based on the Houston, Alan cries out his experience as the founder of the online community 420 InvestorThe first and still the biggest decent diligent platform focused on the shares sold in the cannabis industry. Alan continues to find new ways to connect industry and facilitate its sustainable growth in the Canepuni community. Approximately New hemp enterprisesHe is responsible for content development and strategic alliances. Until the early 2013 focuses on the cannabis industry, Alan, who began his career in Wall Street, worked as more than two decades of research and portfolio. Article 650 of the Article 650 published in 2007 Looking for alphaWhere he has 70,000 followers, Alan is a frequent speaker for industry conferences and a Frequent source The media, including NY Times, Wall Street Journal, Fox Business and Bloomberg TV. Contact Alan. Ration | Facebook | Connection | Email
Statistics Canada has released February retail sales for the country, with Cannabis sales are declining from January levels, down 7.9% from the previous month to C$440.5 million. The sequential decrease increased by 2.0% on a daily basis due to fewer days than in the previous month. January, originally reported at C$466.1 million, was revised higher to C$478.2 million. February sales rose 7.9% from a year ago, down 9.4% from last month, and 8.3% in May and 7.5% in June, but better than last year’s slowest growth rate since legalization -0.9% in September 2024 due to the BC strike. Total sales are expected to increase by 4.5% to C$5.39 billion in 2024 and by 4.1% to C$5.62 billion in 2025. So far in 2026, sales are up 8.6%.
An increase in the number of shops, as well as a fall in the prices of flowers that attract consumers from the illegal market, have boosted sales. In Ontario, the most populous province, sales fell 11.4% from January and 3% from a year ago. Alberta was down 10.2% from January, but up 1% from a year ago. British Columbia was up 3.7% from January and up 33% from a year ago, while Quebec was down 9.6% from January but up 30% from a year ago.
March sales data will be released on May 22.
Based in Houston, Alan leverages his experience as an online community founder 420 Investorthe first and still the largest due diligence platform focused on publicly traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. time New Cannabis Ventureshe is responsible for content development and strategic alliances. Before turning his attention to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst with more than two decades of research and portfolio management experience. A prolific writer, with over 650 articles published since 2007 Looking for Alphawhere he has 70,000 followers, Alan is a frequent speaker at industry conferences and frequent source Media including the NY Times, Wall Street Journal, Fox Business and Bloomberg TV. Contact Alan. Twitter: |: Facebook |: LinkedIn: |: El
Aurora Cannabis accelerates global medical cannabis leadership with proactive acquisition of Safari Flower, expanding EU GMP capabilities to serve growing high-margin international markets.
EDMONTON, AB, April 15, 2026. /PRNewswire/ – Aurora Cannabis Inc. (the “Company” or “Aurora”) (NASDAQ: ACB) (TSX: ACB), a leading global medical cannabis company based in Canada, is pleased to announce that it has acquired Safari Flower, an EU GMP certified cannabis developer and manufacturer. The aggregate consideration is valued at $26.5 million, subject to customary adjustments and including a $2 million cash payment contingent on the satisfaction of certain conditions (the “Deal”).
“The acquisition of Safari Flower is an important milestone for Aurora as we continue to make targeted investments in expanding our EU GMP capabilities to support the rapidly growing international medical cannabis market. The expanded supply chain will enable us to capture greater international market share while delivering superior quality and value to our most valued patients around the world,” said Miguel Martin, Aurora’s Executive Chairman and Chief Executive Officer.
Strategic rationale
Safari Flower Company’s 59,000-square-foot, purpose-built EU GMP certified in-house processing and manufacturing facility in Ontario, Canada will provide the company with increased capacity that closely aligns with its existing cultivation and manufacturing facilities.
The increased capacity will be used to supply EU GMP flower to Aurora’s key international markets, including Germany, Australia, Poland and the UK, and will support further market expansion.
This transaction is expected to result in a positive adjusted EBITDA contribution in fiscal year 2027, with additional benefits in fiscal year 2028 and beyond as these assets are optimized in the Company’s supply chain.
Aurora intends to leverage its plant science and operational expertise to drive operational efficiencies, improve crop yields and support high-margin commercialization in international markets.
Transaction details
Aurora, through a wholly-owned subsidiary, has indirectly purchased 100% of the shares of 9869247 Canada Limited (“Safari Flower Company”) for an aggregate consideration of $26.5 million, including a cash payment of $2 million subject to the satisfaction of certain conditions. As closing consideration, Aurora (i) issued to the selling stockholder 2,417,180 shares of common stock; and (ii) paid the selling stockholder $15 million in cash, subject to customary post-closing adjustments.
About Aurora
Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance and a deep commitment to patient care. Aurora serves both medical and consumer markets in Canada, Europe, Australia and New Zealand with a strategic focus on high margin opportunities and a medical first approach. Aurora’s portfolio of trusted, leading brands includes Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, Tasty’s® and Whistler Medical Marijuana Co.®. With world-class GMP-certified manufacturing facilities in Canada and Germany and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products to open up the world to cannabis.
Learn more at www.auroramj.com and follow us on X and LinkedIn.
Aurora common stock trades on the NASDAQ and TSX exchanges under the symbol “ACB”.
New Cannabis Ventures’ NCV Newswire aims to gather high-quality content and information about leading cannabis companies to help our readers filter through the noise and stay on top of the most important cannabis business news. The NCV Newswire is edited by an editor and is not automated in any way. Got a secret news tip? Get in touch.
You are reading this week’s edition of New Cannabis Ventures, a weekly magazine we have published since October 2015. The newsletter includes unique insight to help our readers stay ahead of the curve, as well as links to the most important news of the week. We no longer email them like we used to, but post this and all newsletters on our website here.
friends,
Just before Christmas, this newsletter discussed how Vireo Growth is getting pretty big. At the end of January I profiled how Vireo Growth is expanding its business. This week’s newsletters include six articles we’ve run since April 2, and Vireo Growth is central to two of them. Vireo Growth is big and getting bigger, but few people seem to care.
I’m not writing this to tell readers to care. In fact, while I used to include the company on my Focus List at 420 Investor, I no longer do. Earlier this month I wrote an article for my subscribers about why I keep looking at things but not including stocks in my Focus List. Here is the summary.
I watch VREOF because it is now one of the largest MSOs by revenue, but it continues to fall short of joining the Global Hemp Stock Index due to its low trading volumes. Average daily trading volume over the past month was 251,000 shares, which is about $100,000 in daily trading value. This is well below peers. Perhaps more importantly, the current price of $0.45, which is down 26.6% year-to-date, is significantly lower than the price of $0.625 for the last large cap in 2024. Not only are the investors not winning, but VREOF hsa distributed a lot of shares to the sellers and they are also under water.
Maybe Vireo Growth shares will reward their owners, or maybe it will continue to do so. I think hemp stock investors and debt holders should be asking why no one is thinking of this yet. Scotts Miracle-Gro, which has been public since 1992 and has a market cap of $3.6 billion, picked up much of VREOF’s stock when it spun off Hawthorne. The 213 million shares are “at an implied price of $0.60” per share, although VREOF hasn’t traded at $0.60 since January. When the divestiture was announced in late January, Vireo Growth closed at $0.5553.
So a large MSO that has reshuffled its management, is now in multiple markets, and has executed its plan to get bigger with several acquisitions, is still not responding to the cannabis investment community. I wish them the best.
Sincerely,
Alan:
New Cannabis Ventures publishes curated articles as well as exclusive news. Here is what we have published in the last 2 weeks.
Follow Alan for real-time updates X.com:. Share and discover industry news with like-minded people on the largest group of cannabis investors and entrepreneurs LinkedIn:.
Stay on top of the most important communications from public companies by watching what’s coming cannabis investor calendar.
Based in Houston, Alan leverages his experience as an online community founder 420 Investorthe first and still the largest due diligence platform focused on publicly traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. time New Cannabis Ventureshe is responsible for content development and strategic alliances. Before turning his attention to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst with more than two decades of research and portfolio management experience. A prolific writer, with over 650 articles published since 2007 Looking for Alphawhere he has 70,000 followers, Alan is a frequent speaker at industry conferences and frequent source Media including the NY Times, Wall Street Journal, Fox Business and Bloomberg TV. Contact Alan. Twitter: |: Facebook |: LinkedIn: |: El
